Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo

Laboratory investigation

Restricted access

Object

Irinotecan (CPT-11), a topoisomerase I inhibitor, is a cytotoxic agent with activity against malignant gliomas and other tumors. After systemic delivery, CPT-11 is converted to its active metabolite, SN-38, which displays significantly higher cytotoxic potency. However, the achievement of therapeutically effective plasma levels of CPT-11 and SN-38 is seriously complicated by variables that affect drug metabolism in the liver. Thus the capacity of CPT-11 to be converted to the active SN38 intratumorally in gliomas was addressed.

Methods

For in vitro studies, 2 glioma cell lines, U87 and U251, were tested to determine the cytotoxic effects of CPT-11 and SN-38 in a dose-dependent manner. In vivo studies were performed by implanting U87 intracranially into athymic/nude mice. For a period of 2 weeks, SN-38, CPT-11, or vehicle was administered intratumorally by means of an osmotic minipump. One series of experiments measured the presence of SN-38 or CPT-11 in the tumor and surrounding brain tissues after 2 weeks' exposure to the drug. In a second series of experiments, after 2 weeks' exposure to the drug, the animals were maintained, in the absence of drug, until death. The survival curves were then calculated.

Results

The results show that the animals that had CPT-11 delivered intratumorally by the minipump expressed SN-38 in vivo. Furthermore, both CPT-11 and SN-38 accumulated at higher levels in tumor tissues compared with uninvolved brain. Intratumoral delivery of CPT-11 or SN-38 extended the average survival time of tumor-bearing animals from 22 days to 46 and 65 days, respectively.

Conclusions

These results demonstrate that intratumorally administered CPT-11 can be effectively converted to SN-38 and this method of drug delivery is effective in extending the survival time of animals bearing malignant gliomas.

Abbreviations used in this paper: AED = antiepileptic drug; CES2 = carboxylesterase 2; CPT-11 = irinotecan; HPLC = high-performance liquid chromatography; IC50 = 50% inhibiting concentration; MTT = methylthiotetrazole; PBS = phosphate-buffered saline.

Article Information

Address correspondence to: Thomas C. Chen, M.D., Ph.D., Department of Neurosurgery, University of Southern California, Los Angeles, California 90033. email: tcchen@usc.edu.

Please include this information when citing this paper: published online April 23, 2010; DOI: 10.3171/2010.2.JNS09719.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Cytotoxic activity of CPT-11 and SN-38 in vitro. Both U87 and U251 glioblastoma cells were treated with increasing concentrations of CPT-11 or SN-38. After 48 hours, cell viability was determined by MTT assay. Shown is the average survival (mean ± SD), where viability of untreated cell cultures was set at 100%. The SN-38 was substantially more cytotoxic than CPT-11, with an IC50 of 750 nM versus 85 μM in U87, and 10 nM versus 10 μM in U251, respectively.

  • View in gallery

    Survival in an orthotopic tumor model after drug treatment. Mice with orthotopically implanted U87 glioblastoma cells received intratumoral delivery of either PBS (control), CPT-11, or SN-38 for 2 weeks via an osmotic minipump. Thereafter, their survival was monitored and the results plotted in a Kaplan-Meier survival curve. Compared with control animals, the survival of both groups of drug-treated animals was prolonged significantly (p < 0.0001). The results also illustrated a significant difference in survival times in animals treated with SN-38 in comparison with those treated with CPT-11 (p < 0.0001).

  • View in gallery

    Presence of SN-38 in tumor tissue after treatment with CPT-11 in vivo. Mice with orthotopically implanted U87 glioblastoma cells received intratumoral delivery of PBS (control), CPT-11, or SN-38 via an osmotic minipump. At the end of the 2-week treatment, the animals were killed and the tumors were harvested. The amount of SN-38 in tumor extracts was quantified by HPLC. Shown is the average amount of SN-38 (mean ± SD, 5 animals per group) in the 3 treatment groups. ***p < 0.005.

  • View in gallery

    Biodistribution of SN-38 after intratumoral delivery. Mice with orthotopically implanted U87 glioblastoma cells received intratumoral delivery of either PBS (control), CPT-11, or SN-38. At the end of the 2-week treatment, all animals were sacrificed and tumors, as well as cerebellum and other normal brain tissue, were harvested. The amount of SN-38 in tissue extracts was quantified by HPLC. Shown is the average amount of SN-38 (mean ± SD; n = 5) in the 3 treatment groups.

  • View in gallery

    Biodistribution of SN-38 compared with CPT-11. Mice with orthotopically implanted U87 glioblastoma cells received intratumoral delivery of PBS (control), CPT-11, or SN-38. At the end of the 2-week treatment, all animals were sacrificed and tumors, as well as cerebellum and other normal brain tissues, were harvested. The amount of SN-38, as well as CPT-11, in tissue extracts was quantified by HPLC. Shown is the average amount of SN-38 (right bar graph) and CPT-11 (left bar graph) as mean ± SD (n = 5) in the 3 treatment groups.

References

  • 1

    Ando YHasegawa Y: Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev 37:5655742005

  • 2

    Ando YSaka HAndo MSawa TMuro KUeoka H: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:692169262000

  • 3

    Bergers GBenjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:4014102003

  • 4

    Chen TCSu SFry DLiebes L: Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 97:9 Suppl236323732003

  • 5

    Comella PLorusso VMaiorino LCasaretti RCannone MMassidda B: Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol 64:8938992009

  • 6

    Innocenti FUndevia SDIyer LChen PXDas SKocherginsky M: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:138213882004

  • 7

    Jansman FGSleijfer DTde Graaf JCCoenen JLBrouwers JR: Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 24:3533672001

  • 8

    Kaneda NHosokawa YYokokura TAwazu S: Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats. Biol Pharm Bull 20:9929961997

  • 9

    Kawato YAonuma MHirota YKuga HSato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:418741911991

  • 10

    Krauze MTNoble COKawaguchi TDrummond DKirpotin DBYamashita Y: Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 9:3934032007

  • 11

    Kuhn JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Williston Park) 16:8 Suppl 733402002

  • 12

    Kuroda JKuratsu JYasunaga MKoga YSaito YMatsumura Y: Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 124:250525112009

  • 13

    Kweekel DGuchelaar HJGelderblom H: Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34:6566692008

  • 14

    Noble COKrauze MTDrummond DCYamashita YSaito RBerger MS: Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 66:280128062006

  • 15

    Perucca E: Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:2462552006

  • 16

    Prados MDLamborn KYung WKJaeckle KRobins HIMehta M: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8:1891932006

  • 17

    Quinn JAJiang SXReardon DADesjardins AVredenburgh JJGururangan S: Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer 115:296429702009

  • 18

    Rivory LP: Metabolism of CPT-11. Impact on activity. Ann N Y Acad Sci 922:2052152000

  • 19

    Santisteban MBuckner JCReid JMWu WScheithauer BWAmes MM: Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 92:1651752009

  • 20

    Santos AZanetta SCresteil TDeroussent APein FRaymond E: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:201220202000

  • 21

    Verschraegen CFJaeckle KGiovanella BKnight VGilbert BE: Alternative administration of camptothecin analogues. Ann N Y Acad Sci 922:2372462000

  • 22

    Vredenburgh JJDesjardins AReardon DAFriedman HS: Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11:80912009

  • 23

    Xu GZhang WMa MKMcLeod HL: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:260526112002

  • 24

    Zhang WXu GMcLeod HL: Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol 10:3743802002

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 121 121 17
Full Text Views 163 163 3
PDF Downloads 61 61 1
EPUB Downloads 0 0 0

PubMed

Google Scholar